Applied NeuroSolutions, Inc.
Alzheimer's disease strikes about 10 percent of people over 65 and up to 50 percent of people over the age of 85. According Applied NeuroSolutions Inc. (OTCBB: APNS), Alzheimer's affects an estimated 4.5 million people in the U.S. The Illinois-based biopharmaceutical company focuses on diagnostics and therapeutics for the treatment of Alzheimer's and has established a relationship with Albert Einstein College of Medicine (AECOM) which grants Applied NeuroSolutions licensing rights to market discoveries made in the neurodegenerative arena. The company is currently working to identify drugs interfering with pathways to prevent disease development through both Therapeutic and Diagnostic Programs. Fighting…